BE@Work: Brief Exercise at Work

April 8, 2019 updated by: Naomi Burn, Teesside University

BE@Work: A Pilot Controlled Before and After Trial of a Workplace Physical Activity Programme.

BE@Work (Brief Exercise at Work) is a pilot controlled before and after trial of a workplace physical activity programme.

Study Overview

Status

Completed

Detailed Description

The aim of this study is to investigate the effect of an 8 week workplace physical activity programme on various markers of physical fitness, cardiometabolic health and wellbeing of employees. The primary outcome measures are the following: aerobic fitness, grip strength, leg extensor power, blood pressure, fasting blood glucose levels, lipid profiles, body mass index, waist and hip circumference and self-report measures of psychological wellbeing. The secondary outcome measure is total physical activity. The primary and secondary outcomes measures will be assessed in the control and intervention groups at baseline and at the end of the intervention (8 weeks).

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants will be adult (≥18 years) with no health conditions that preclude them from exercise (information obtained via their self-report) and able to understand written and spoken English. Participants will be cleared for exercise participation via the Physical Activity Readiness Questionnaire Plus (PARQ+)

Exclusion Criteria:

  • Exclusion criteria are: Individuals who are not cleared for exercise participation via the PARQ+ will not be eligible to participate. Additionally those unable or unwilling to give informed consent, have any diagnosis or symptoms of cardiovascular or metabolic disease (such as history of heart attack, stroke or diabetes), have been advised by a health professional to avoid physical exercise or activity, are pregnant or might be pregnant and cannot understand and speak English will not be eligible to participate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention arm

8 week workplace based exercise programme, 3 exercise sessions each week. Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be supervised and conducted in groups, with the option to request individual one-to-one sessions if preferred.

Outcome measures assessed at baseline and follow-up (8 weeks)

• Exercises will be conducted in an interval training format (60 second exercise bursts, followed by 75 seconds rest). The exercise bursts are designed to elicit ≥85% of participants age predicted maximum heart rate and will be tailored to each individuals fitness level and ability. Exercise sessions will be conducted 3 times per week for 8 weeks and will last between 15-25 minutes.
No Intervention: Control
Outcome measures only at baseline at follow-up (8 weeks)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Aerobic fitness
Time Frame: 8 weeks
Chester step test. This involves stepping onto and off a box at a height relevant to the participants age and usual physical activity level, at a set pace for a maximum of 10 minutes or until the participants heart rate reaches ≥80% of age-predicted maximum, whichever is first. Second-to-second heart rate (HR) will be monitored using a wrist worn heart rate monitor (Polar A360, Polar Electro Oy, Finland).
8 weeks
Alternative measure of aerobic fitness
Time Frame: 8 weeks
If the participant chooses, they can also have their aerobic fitness measured using a ramp test. This will involve attending the Exercise Physiology Laboratory at Teesside University. Peak oxygen uptake will be measured by a ramp test on an electromechanically braked cycle ergometer (Lode Excalibure, Groningen, Netherlands). Participants will perform 5 minutes of submaximal exercise as a standard warm-up. Beginning with no load, power output will increase by 30 Watts (W) per minute until volitional exhaustion or the subject can no longer maintain a pedal cadence of 70-90 revolutions per minute. Expired gas will be collected and analysed throughout (Zan 600 USB CPX, nSpire Health Inc., United Kingdom), with peak oxygen uptake defined as the peak value of a 5-point average data set).
8 weeks
Hand grip strength
Time Frame: 8 weeks
Hand grip strength will be measured using a hand dynamometer. The participant will stand with arms at their side, not touching their body holding the dynamometer in their non-dominant hand. The participant will be asked to squeeze the dynamometer with as much force as possible.
8 weeks
Leg extensor power
Time Frame: 8 weeks
Leg extensor power will be assessed using the Nottingham leg extensor power rig, (Medical Engineering Unit, University of Nottingham, Nottingham, UK). The participant is seated in an adjustable seat and presses a foot pedal until the leg is extended. This petal accelerates a flywheel, and it is this average power in watts that is measured.
8 weeks
Resting blood pressure
Time Frame: 8 weeks
Resting blood pressure will be measured using an electronic blood pressure monitor (Omron, M6 AC ME, Omron Healthcare, Kyoto, Japan).
8 weeks
Blood lipid concentration
Time Frame: 8 weeks
Blood lipids will be assessed from a finger prick blood sample using the Cholestech LDX analyser (Cholestech Corporation, Hayward, CA, USA). The LDX analyser is currently used for the National Health Service Health Checks. Standard aspectic techniques will be used. A small puncture will be made in the middle finger using a one piece single use finger stick. The sample will be drawn into a 35 μL capillary tube and immediately transferred into a cassette sample well. The cassette will then be placed into the device drawer for analysis.
8 weeks
Body Mass Index
Time Frame: 8 weeks
Body mass index will be calculated using the standard formula in units of kg/m2. Measurements of height and body mass will be taken using a standard scale and stadiometer.
8 weeks
Health related quality of life
Time Frame: 8 weeks
Health related quality of life will be measured using a validated self-report paper based questionnaire (SF-36) (RAND, 2016). High scores mean higher quality of life.
8 weeks
Mental wellbeing
Time Frame: 8 weeks
Mental wellbeing will be assessed using a validated self-report paper based questionnaire (Warwick Edinburgh Mental Wellbeing Scale) (Tennant et al., 2007). The total score is obtained by summing the score for each of the 14items. Total scores range from 14-70, higher scales indicate higher mental wellbeing.
8 weeks
Stress
Time Frame: 8 weeks
Stress will be measured using a validated self-report paper based questionnaire (Perceived Stress Scale) (Cohen & Williamson, 1988). Scores ranging from 0-13, 14-26 and 27-40 would be considered low, medium and high perceived stress, respectively.
8 weeks
Blood glucose concentration
Time Frame: 8 weeks
Fasting blood glucose (mmol/L) will be assessed from a finger prick blood sample using the Cholestech LDX analyser (Cholestech Corporation, Hayward, CA, USA). The LDX analyser is currently used for the National Health Service Health Checks. Standard aspectic techniques will be used. A small puncture will be made in the middle finger using a one piece single use finger stick. The sample will be drawn into a 35 μL capillary tube and immediately transferred into a cassette sample well. The cassette will then be placed into the device drawer for analysis.
8 weeks
Waist circumference
Time Frame: 8 weeks
Waist and hip circumference will be measured using non-elastic Gulick tape measure (G-tape) at the narrowest point of the waist and broadest part of the hip.
8 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accelerometer assessed habitual physical activity
Time Frame: 8 weeks
Measurement of habitual physical activity over a 7 day period will be assessed using a Uniaxial Actigraph accelorometer (GT1M model, Actigraph, LLC, Pensacola, Florida). The participant will wear a small hip mounted accelerometer to assess their habitual physical activity for 7 days following their baseline data collection.
8 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 9, 2018

Primary Completion (Actual)

October 31, 2018

Study Completion (Actual)

October 31, 2018

Study Registration Dates

First Submitted

March 5, 2018

First Submitted That Met QC Criteria

March 9, 2018

First Posted (Actual)

March 16, 2018

Study Record Updates

Last Update Posted (Actual)

April 10, 2019

Last Update Submitted That Met QC Criteria

April 8, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • 036/18

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on High-intensity Interval Training

Clinical Trials on High-intensity interval training

Subscribe